Lucas A. Horn, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 8B14
- Bethesda, MD 20892
- 240-858-3472
- lucas.horn@nih.gov
RESEARCH SUMMARY
Dr. Horn’s current research involves the development of innovative combination therapies for the treatment of cancer. His focus is on understanding mechanisms of tumor progression and therapy resistance, including the influence of tumor cell plasticity and the tumor extracellular matrix on immune cells in the tumor microenvironment.
Areas of Expertise
Lucas A. Horn, Ph.D.
Research
The main goal of our research is to design and assess the efficacy of novel combination immunotherapies for the treatment of a range of human carcinomas. Our hypothesis-driven preclinical studies are used as rationale for the translation of these therapies into novel clinical trials. To achieve this goal, our research has focused on elucidating how mechanisms of tumor progression and therapy resistance, including tumor cell plasticity, tumor extracellular matrix, suppressive immune cells, and other factors influence the interplay of immune cells and tumor cells in the dynamic tumor microenvironment.
Publications
- Bibliography Link
- View Dr. Horn's PubMed Summary.
Tumor plasticity and resistance to immunotherapy
Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity
The use of a humanized NSG-β2m -/- model for investigation of immune and anti-tumor effects
Biography
Lucas A. Horn, Ph.D.
Dr. Lucas Horn received his Ph.D. in Biological Sciences from the University of Maryland Baltimore County (UMBC) in 2017. He subsequently joined the Laboratory of Tumor Immunology and Biology (LTIB), Center for Cancer Research, NCI, NIH, as a Postdoctoral Fellow, and was appointed as a Staff Scientist in 2020. He is currently a Staff Scientist in the Center for Immuno-Oncology's Translational Research area. Dr. Horn’s current research is focused on the development of novel immunotherapeutic approaches aimed at promoting immune cell activation while altering tumor cell plasticity and the suppressive tumor microenvironment.